ALung Technologies recently announced the initiation of patient enrollment in its VENT-AVOID trails with the Minneapolis Heart Institute Foundation. The trial is pivotal in validating the safety and efficacy of the Hemolung Respiratory Assist System for COPD patients who require ventilatory support.
Recent Posts
Meet the Executive: Tal Heppenstall, President of UPMC Enterprises
It’s been five years since UPMC rebranded its long-standing work on health care innovation and …
Read More →
RxAnte launches technology-enabled comprehensive pharmacy service for medically complex and vulnerable Medicare members
RxAnte, a UPMC Enterprises portfolio company, recently developed and launched a transformative direct-to-member service that …
Read More →